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Background: So far, many studies have shown that the risk of developing seizures
and epilepsy is higher among patients with multiple sclerosis (MS) than in the general
population. However, the causal link between these two diseases is still unclear. In
addition, it is not clearly understood whether and to what extent the manifestation of
seizures and epilepsy in patients with MS affects the clinical course and the long-term
prognosis of the disease. We aimed to retrospectively identify and describe patients with
MS and with seizures and epilepsy which were seen at the Department of Neurology of
the University of Regensburg in Germany between the years 2003–2015.
Methods: With the help of the electronic documentation system of hospital admitted
patients followed by scrutinizing medical records of patients with MS for evidence of
seizures and epilepsy, we identified patients with MS and seizures or epilepsy.
Results: We identified 22 individuals (1.74%) out of 1,267 patients with MS with
seizures or epilepsy. 18 of these 22 individuals met criteria for epilepsy (1.42%). Nine MS
patients (40.9%) suffered from relapsing-remitting MS (RRMS) whereas 11MS patients
(50.0%) showed a secondary progressive disease course (SPMS). Five of those (45.5%)
converted from RRMS to SPMS before they acquired epilepsy. None of the identified
patients with MS and seizures or epilepsy suffered from primary progressive MS (PPMS).
Moreover, two MS patients (9.1%) had a history of seizures before MS onset. Seizures
were of focal onset in 17 patients with MS (77.3%). Fourteen out of these 17MS patients
presented with focal to bilateral tonic-clonic seizures (82.4%). Five MS patients (22.7%)
showed tonic clonic seizures of unknown onset. Status epilepticus was reported in three
patients with MS (13%), for one patient the data was inconclusive.
Conclusion: The occurrence of seizures and epilepsy was higher than in the general
population, suggesting a causal relationship between both diseases. In most cases,
seizures occurred after the first manifestation of MS. The high frequency of focal seizures
supports the concept of cerebral lesions in patients with MS playing an important role in
precipitation of seizures and epilepsy.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disease of the
central nervous system (CNS) (1) which predominantly affects
young adults, often female (2), and is of autoimmune origin
(3). Because of the high variability in its clinical presentation,
MS shows a wide range of different signs and symptoms (4).
The appearance of seizures has previously been recognized
as part of the MS disease spectrum (5). Although seizures
are a rare manifestation in patients with MS, several studies
indicate that the risk of developing seizures and epilepsy is
three to six times higher in patients with MS compared to the
general population (6–9). However, the underlying cause of the
simultaneous occurrence of both diseases could not be described
so far (4), and the pathophysiological mechanisms explaining
this relationship are subject of current research (10). In addition,
it is not clearly understood whether and to what extent the
manifestation of seizures and epilepsy in MS patients affects the
clinical course and the long-term prognosis (7, 9, 11).
The aim of this study was to identify and describe the patients
who presented with MS and with seizures and epilepsy of the
Department of Neurology at the University of Regensburg in
Germany between 2003 and 2015. A comprehensive overview
as well as a detailed characterization of this group of patients
has been generated to allow the investigation of a potential
contribution of inflammation and evolution of the lesions driving
MS pathogenesis and progression to the manifestation of seizures
and epilepsy.
SUBJECTS AND METHODS
The study was approved by the Ethics Committee of the
University of Regensburg, Germany (Approval number: 16-101-
0069). The period in which the analyzed data was collected
ranged from April 15, 2016 to July 15, 2016. We identified 23
individuals out of 1267 patients with MS which simultaneously
suffered from MS and seizures or epilepsy and presented
themselves at the Department of Neurology of the University
of Regensburg in Germany between 2003 and 2015. All patients
with MS of the Department of Neurology of the University of
Regensburg in this period are captured in this study and therefore
there is no potential selection bias. As it is a retrospective
study, the identification of the individuals was done with the
help of the electronic admission system of the hospital and a
computer search query, as well as by scrutinizing medical records
of the MS patients for evidence of seizures and epilepsy within
the individual archives of the hospital. Every single patient of
the clinic is well documented in electronic and non-electronic
form, so there is no anonymised data. The ICD numbers for
MS–ICD-10: G.35–and for epilepsy–ICD-10: G.40–were used
as search criteria for electronic search. In the following, the
dates of birth of individual persons could be determined by
archived physician letters and thus the associated files could be
analyzed. No patients with clinically isolated syndromes (CIS) or
pseudo tumoral presentation of MS were found in the records.
As diagnostic criteria for MS the Poser criteria were used for
all patients with first diagnosis of MS before 2001 and the
McDonald criteria for patients with first diagnosis of MS after
2001. The Poser criteria differentiated between clinically definite
MS, laboratory-supported definite MS, clinically probable MS
and laboratory-supported probable MS based on clinical and
paraclinical findings. Due to their early publication in 1983, they
do not contain any MRI criteria for diagnosis (12). MRI findings
are used with the McDonald criteria which have been revised
several times within the last years (13).
Criteria of the International League Against Epilepsy (ILAE)
of 2017 by Scheffer et al. were used to define epilepsy (14).
Seizures were classified accordingly to Fisher et al. and arranged
in seizures of focal, generalized, and unknown onset (15). Time
zero for epilepsy was taken as the appearance of the first seizure.
Subsequently, the medical records of the patients withMS and
seizures or epilepsy were collected and retrospectively reviewed.
On this occasion the data and medical history of the individuals
were evaluated in tabular and graphic form. Microsoft Office
Word and Excel as well as the statistic program SPSS (version
23.0) were used. Thus, a detailed characterization of this cohort
of MS patients and a description of the individual disease courses
could be performed. The review of the individual patient records
also revealed that some data were missing or incomplete, partly
because some of the patients did not come to follow up visits after
the first disease manifestation. As a result, the disease course of
some patients could not be fully or completely reviewed.
RESULTS
Number of Cases
We identified 23 individuals (1.82%) out of 1,267 patients with
MS which suffered from seizures or epilepsy and presented
themselves at the Department of Neurology of the University
of Regensburg between the years 2003 and 2015. One out of 23
patients was excluded from the analysis because of intravenous
drug abuse already in childhood. Accordingly, 22MS patients
(1.74%) which have had seizures or epilepsy remained. Eighteen
of these 22 individuals met criteria for epilepsy (1.42%) (14),
the other four persons had only exhibited one single seizure at
time of data collection. Three of those patients had their first
seizure at the time of latest presentation to the Department
of Neurology of the University of Regensburg, one patient
developed the first seizure a few years prior to the most recent
follow up after sudden discontinuation of long-term medication
with carbamazepine during an acute relapse of MS. The available
data did not allow comparing the epilepsy incidence between
patients with McDonald and Poser criteria, as all MS patients of
the Department of Neurology of the University of Regensburg
would have needed to be classified regarding these two criteria.
Characteristics of Cases With Regard to
MS
The mean age at the time of data collection was 48.5 ± 15.2
years (range 18–76 years) and most patients were females (17
females, 77.3%; 5 males, 22.7%). The mean age at the onset of
the first symptoms of MS was 25.3 ± 8.7 years (range 14–42
years). Nine out of 22 patients (40.9%) suffered from relapsing-
remitting MS (RRMS), whereas 11 patients (50.0%) showed a
Frontiers in Neurology | www.frontiersin.org 2 June 2019 | Volume 10 | Article 613
Schorner and Weissert Seizures and Epilepsy in MS
secondary progression of their disease (SPMS). Two patients
(9.1%) could not be assigned to any MS type because the disease
courses were unspecified in the medical records. There was
no reported case of primary progressive MS (PPMS) in the
investigated patient population. The mean duration of MS at
the time of data collection was 24.87 ± 10.3 years (range 6–40
years). The most common symptoms at the first onset of the
MS disease manifestation were sensory disturbances followed by
visual impairment.
Ten of the 22 patients with MS (45.5%) were treated
with interferon-beta at any time during their disease course.
Other immunomodulatory medications used for treatment of
MS included azathioprine (n = 6), mitoxantrone (n = 5),
glatiramer acetate (n = 4), natalizumab (n = 4), and fingolimod
(n = 3); baclofen was used for symptomatic treatment of
spasticity (n= 5).
Manifestation of Seizures in the Disease
Course of MS
Two patients (9.1%) had a history of seizures before MS onset
and 16 patients (72.7%) had experienced seizures after the onset
of the disease. The first appearance of seizures for the remaining
four patients (18.2%) could not be clarified by the assessment of
their medical records. Nine patients with MS (40.9%) had RRMS
at the time of first seizure.
Eleven patients developed SPMS (50.0%). Five of those
patients (45.5%) converted from RRMS to SPMS before and
four patients (36.4%) after they developed seizures. The medical
records of the remaining two patients (18.2%) did not contain
enough information to draw a conclusion on the transition point
to SPMS.
Characteristics of Seizures and Treatment
Seizures were of focal onset in 17 patients (77.3%). Fourteen
out of these 17 patients presented with focal to bilateral tonic-
clonic seizures (82.4%). Furthermore, five patients (22.7%)
showed tonic-clonic seizures of unknown onset. Three of those
were diagnosed with unknown epilepsy; two were not seen
any more in the hospital after their first seizure. Fourteen
patients developed bilateral tonic-clonic seizures (63.6%) after
initial presentation with focal seizures; five patients suffered
from tonic-clonic seizures of unknown onset (22.7%). Therefore,
a total of 19 patients suffered from seizures involving both
hemispheres (86.4%). One of the five patients with tonic-clonic
seizures of unknown onset showed hippocampal atrophy inNMR
imaging studies. In one of these patients an ictal EEG with
event-related potentials was recorded, in three other patients
only interictal EEGs were recorded. Two of those showed
abnormalities such as focal slowing or dysrhythmia. In one
patient no EEG recordings were performed. Altogether, three
of these five patients with tonic-clonic seizures of unknown
onset were classified as having an unknown epilepsy type.
Status epilepticus was reported in three patients (13.6%),
for one patient the data was inconclusive. In two patients
with MS and seizures (9.1%) other factors were identified
which may have contributed to the occurrence of seizures
namely dehydration and hypokalaemia as well as alcohol abuse.
However, after careful consideration and detailed assessment
of the patient files, these two patients were not excluded from
the analysis.
The frequency and the severity of the seizures varied from
patient to patient. In the assessed time window in 21 individuals
(95.7%) at least one antiepileptic drug therapy was documented
at the time point of data collection. The most commonly
used antiepileptic drugs included levetiracetam, lamotrigine,
carbamazepine, and valproate. Less used medication contained
lorazepam, gabapentin, phenytoin, and lacosamide. Both mono-
and polytherapies were prescribed, with nine patients requiring
only one drug to treat their seizures. All other patients received
at least two different medications during the assessment period.
Only one patient did not receive any antiepileptic drug. Some
patients had an excellent response to anticonvulsive therapy,
whereas the epilepsy of the other part of the group of patients
seemed to be difficult to control and was characterized by
recurrent seizures of varying frequencies. In seven patients the
emergence of seizures could be controlled. The other seven
patients seemed to suffer from drug-resistant seizures. One more
patient developed recurrent seizures probably because of non-
compliant drug use. Five patients had their first seizure and did
not present to the clinic again prior to the time of data collection,
so it remains unclear whether these patients developed more
seizures under antiepileptic therapy or not. Documentation was
incomplete for two of the patients and therefore no statement
regarding therapy response can be made.
Unfortunately, it was difficult to compare epilepsy outcome
based on the use of immunomodulatory or symptomatic MS
treatment due to irregular presentation of some patients at
the Department of Neurology of the University of Regensburg
resulting in insufficient information being available on this
subject. Nevertheless, an increased frequency of seizures could
be determined in two individuals whose medication was changed
to fingolimod.
The characteristics of the 22 described individuals are
presented in Table 1.
DISCUSSION
Even though seizures only affect a minority of patients with MS,
they are still a serious problem (5). The occurrence of seizures
has previously been considered as part of the disease spectrum of
MS. Several studies indicate that the risk of developing seizures
is up to six times higher in MS patients compared to the general
population (6–9).
It is well-known that MS is not only a disease of the
white matter of the cerebral cortex, but also affects the gray
matter (16, 17) and that atrophy and lesions in this part of
the brain are more frequent than previously suggested (4).
This leads to the assumption that cortical and subcortical
lesions as well as surrounding oedema in MS may play an
epileptogenic role. An increased number of these lesions in
MS patients with comorbid seizures and epilepsy has been
reported as compared to MS patients without seizures (5,
12, 18). NMR-tomographic studies have shown an association
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TABLE 1 | Overview of the MS patients with epileptic seizures at the Department of Neurology of the University of Regensburg which have presented themselves between 2003 and 2015.
Age
range*
Age
(years)
fm MS
Age
(years)
fd MS
Disease
course
of MS
Disease
state
of MSa
Duration
of MS
(years)a
Age
(years)
fm EP
Age
(years)
fd EP
FS FBTCS TCSUO Status
epilepticus
MS
before
EP
EP
before
MS
IFN-
betab
Drug
resistant
epilepsy
45-60 38 40 RRMS RRMS 2 40 40 + + – – + – – –
18–30 15 15 RRMS RRMS 6 21 21 – – + – + – + –
45–60 14 35 RRMS→ SPMS SPMS 21 34 35 + + – + + – – +
31–45 14 16 RRMS RRMS 15 28 29 + – – – + – + +
18–30 × 18 RRMS RRMS × 23 23 + + – – + – – –
45–60 19 21 RRMS→ SPMS SPMS 30 49 49 + + – – + – – –
45–60 28 28 RRMS→ SPMS SPMS 22 50 50 + + – – + – + –
60–80 × × RRMS→ SPMS SPMS × 60 60 – – + – + – – ×
45–60 × 29 RRMS RRMS × 45 45 – – + + + – + +
60–80 33 36 RRMS→ SPMS × 22 55 55 – – + + + – – ×
45–60 26 26 RRMS→ SPMS SPMS 26 52 52 + + – + + – – –
31–45 20 20 RRMS→ SPMS RRMS 12 32 32 + + – – + – + –
45–60 25 25 RRMS→ SPMS RRMS 16 × 41 + + – – + – + –
60–80 42 62 × × 19 59 61 + – – – + – – ×
18–30 × 12 RRMS RRMS × 12 12 + + – – + – + –
60–80 × 39 × × × × × + + – – × × + +
31–45 29 30 RRMS × × 15 16 + + – – – + – –
45–60 34 44 RRMS × 0 33 34 + + – – – + + +
60–80 × 32 RRMS→ SPMS × × × × + – – – × × – ×
31–45 × 20 RRMS→ SPMS × × × 12 + + – – × × – +
31–45 21 24 RRMS RRMS 8 29 29 + + – – + – + +
31–45 21 24 RRMS→ SPMS × × × × – – + – × × – –
Mean 47.7 24.9 28.0 9.0 37.5 36.6
Range 18 – 76 14 – 42 12 – 62 0 – 30 12 – 60 12 – 61
In order to protect the identity of the individuals and since it is a requirement of the journal, age ranges were used instead of the exact ages of the patients.
*At data collection.
aAt time of epilepsy diagnosis.
fm, first manifestation; fd, first diagnosis; FS, Seizures of focal onset includes FAS (focal aware seizures) and FAIS (focal impaired awareness seizures); FBTCS, focal to bilateral tonic-clonic seizures; TCSUO, tonic-clonic seizures of
unknown onset; EP, epilepsy; IFN, interferon; x, unknown.
bTherapy with interferon-beta at any time during the disease course of MS.
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between gray matter lesions and the appearance of epilepsy
(7, 19–21). A recent study of Burman et al. demonstrated
an association between epilepsy and a progressive disease
course, possibly due to gray matter lesions (22, 23). The
increased lesion load possibly results in a demyelinated area
with a higher risk of epileptogenic potential (24). Furthermore,
some medications used in treating MS, such as baclofen or
interferon beta, may increase the risk of generating seizures. The
proconvulsive properties of some drugs could be due tometabolic
interference with antiepileptic drugs or due to direct neurotoxic
effects (25, 26).
While the prevalence of epilepsy in the general population
is about 0.27–1.7%, it seems to be three to six times higher in
MS patients (27). Based on several studies by different authors,
prevalence rates of seizures or epilepsy between 0.5 and 8.3% have
been reported (5, 27). We observed a prevalence for seizures of
1.74% and for epilepsy of 1.42% in our MS cohort, because only
18 of the 22 patients met criteria for epilepsy while the other four
patients presented only one seizure. Accordingly, the frequencies
reported by us are lower than the frequency of people having MS
and seizures or epilepsy previously reported in other studies as
shown in Table 2.
Such varying results could be due to selection bias and
differences in methods, definitions and diagnostic criteria (30,
34). For example, the accuracy of the MS diagnosis as well
as the definition of epilepsy and its distinction toward non-
epileptogenic, paroxysmal manifestations of MS, such as tonic
spasm of the extremities, play a crucial role (36). Moreover, the
different composition of the study populations may have also
contributed to the varying results. Some of the listed studies
might have included all MS patients with seizures independent of
these having other reasons for developing seizures than MS. For
example, Catenoix et al. reported a prevalence rate of 2.0% forMS
patients with seizures whereas the prevalence rate was less (1.3%)
when excluding all patients that might have had other reasons
for seizures than MS (28). It has also to be noted that some
studies might have included MS patients who developed their
first seizure long before MS onset, making a relation between
the two diseases rather unlikely (37). Furthermore, it should
be emphasized that no strict diagnostic criteria for MS existed
before 1983 and that magnetic resonance imaging (MRI) was first
introduced in the diagnostic criteria of MS in the mid-1980s (12).
It cannot be excluded that the prevalence rate may have been
underestimated because of the retrospective design of our study.
With a percentage of 77.3 %, women were significantly
overrepresented in our study population. The same gender
preference was shown in other studies by various authors (6,
7, 27, 35, 37), suggesting an increased occurrence of epilepsy
especially in women with MS. In addition, in this study, patients
presented with an average age of 25.3 years at the onset of MS.
Other studies too reported their patients being relatively young
when MS was diagnosed for the first time (10, 38). This in
turn raises the suspicion that the risk of developing epilepsy is
highest among the younger MS patients (10, 38). However, as
MS is generally more likely to affect younger people and among
these predominantly women, these numbers probably reflect the
distribution in the general MS population (2, 6, 35).
The most common symptoms at the first onset of the MS
disease manifestation were sensory disturbances followed by
visual impairment. Symptoms of these functional systems are
among others the most common disease manifestations in MS
patients (39).
Considering the time of first manifestation of seizures and
epilepsy in MS patients, it must be noted that seizures may occur
in any subtype of MS and at any time during the disease course.
Furthermore, the appearance of epileptic symptoms is possible
even before the onset of MS. However, it should be emphasized
that MS itself can exist long before becoming clinically apparent
for the first time (5, 11, 27). The predominant MS subtypes in our
study were RRMS and SPMS. No PPMS patients were present
in our cohort but PPMS patients have been reported in other
studies in which the presentation of MS and epilepsy has been
investigated (6, 10, 21, 22, 25, 26, 28, 30, 40).
As alreadymentioned, focal pathologies of the brain occurring
in MS patients, which are likely supposed to cause increased
excitability of the cerebral cortex, might be the underlying cause
of seizures in these patients (7, 20, 25). The lower frequency of
seizures in patients with PPMSmay be linked to the fact that these
patients show a lower burden of cerebral lesions, predominantly
in form of non-periventricular distribution (23).
Various studies have shown that epilepsy usually occurs in
early stages of MS (11). Seizures may be the first symptom of
MS, however most seizures occur during the disease and thus
after diagnosis of MS (32). The present study confirms that
the majority of seizures occur in patients already diagnosed
with MS. Seizures occurred about 14.92 years (range one to 30
years) after the first manifestation of MS and thus much later as
compared to previously published numbers (7, 20, 28, 32, 35).
However, some studies also reported a larger range between the
first manifestation of MS and occurrence of epilepsy which are
in line with the range presented in the current study (25, 33, 40).
These differences may be explained by the fact that some of these
studies are older and were published at a time when uniform
diagnostic criteria for MS were not yet available and diagnostic
options (e.g., MRI) were limited. Consequently, this may have led
to a later diagnosis of MS and a shorter duration until the first
onset of epilepsy. In addition, the patients’ better understanding
of their disease, their education, the use of self-help groups and
a resulting more conscientious and cautious lifestyle as well as
progress in therapy, especially immunotherapy, may cause a later
appearance of seizures in MS patients (39). Since there was no
patient in this study who showed seizures as the first symptom,
it is suggested that the likelihood of developing seizures and
epilepsy may rise with the duration of MS and the number of
lesions (19).
Some authors mention that, although all types of seizures may
occur inMS, seizures of focal onset aremore common than tonic-
clonic seizures of unknown onset, with a high proportion of focal
to bilateral tonic-clonic seizures among seizures of focal onset
(7, 18, 27, 34). This is in line with the results of our study, in which
77.3% of affected individuals had seizures of focal onset of which
82.4% developed into focal to bilateral tonic-clonic seizures.
Only 22.7% initially had tonic-clonic seizures of unknown onset.
This supports the assumption that local inflammation and lesion
Frontiers in Neurology | www.frontiersin.org 5 June 2019 | Volume 10 | Article 613
Schorner and Weissert Seizures and Epilepsy in MS
TABLE 2 | MS patients observed in other studies of different MS centres and countries and the amount of concomitant seizures in these patients.
References Patients with
MS (n)
Patients with MS
and EP (n)
Patients with MS
and EP (%)
Country Diagnostic criteria
for MS
Benjaminsen et al. (25) 431 19 4.4 Norway Poser/McDonald
Burman et al. (22) 14545 502 3.5 Sweden -
Catenoix et al. (28) 5041 67 1.3 France Poser
Eriksson et al. (29) 255 20 7.84 Sweden Poser
Etemadifar et al. (30) 3522 81 2.3 Iran McDonald
Lund et al. (31) 364 24 6.6 Norway Poser
Moreau et al. (7) 402 17 4.25 France Poser
Olaffson et al. (9) 188 5 2.65 Iceland Poser
Shaygannejad et al. (32) 920 29 3.15 Iran McDonald
Sokic et al. (20) 268 20 7.5 Serbia Poser
Striano et al. (33) 270 13 4.8 Italy McDonald
Uribe-San-Martín et al. (10) 310 10 3.2 Chile McDonald
Viveiros et al. (34) 160 5 2.5 Brasil McDonald
Zare et al. (35) 920 29 3.15 Iran McDonald
evolution in the brain could be the cause of developing epilepsy
when already having MS (10, 25). Three of the five patients
with tonic-clonic seizures of unknown onset were classified as
having unknown epilepsy. No patients with a proven generalized
epilepsy were identified (14).
Whether and to what extent the manifestation of seizures
and epilepsy in MS patients influences the clinical course and
the long-term prognosis of the MS has not been sufficiently
clarified (7, 9, 11). Patients with MS and simultaneously existing
seizures or epilepsy show a higher EDSS score as compared to
MS patients without epileptic manifestations (18, 28, 41). In
addition, seizures are associated with the earlier loss of walking
ability and, consequently, use of a wheelchair, as well as earlier
death (26).
When studying the patients’ medical records, it was apparent
that seizures differed in both severity and frequency, so that
some patients where more affected than others by their disease.
In addition, it could be seen that epilepsy in some patients
was halted when using anticonvulsive therapy while the epilepsy
of the other patients seemed to be drug resistant and difficult
to control by medical therapies, so these patients presented
recurring seizures. Similar findings were reported in a study by
Dagiasi et al. in which the number of seizure free patients was
rather low (42).
In the literature, two different patterns of epilepsy are
distinguished in the case of simultaneously existing MS: the so-
called “benign” and “progressive” course of epilepsy. The benign
form contains an unchanged or even decreasing frequency
of seizures and a regular pattern of their appearance. The
progressive course, however, describes a frequent occurrence
of seizures and a constant development of new types of
seizures (37).
In our study, 50.0% of patients with MS suffered from SPMS.
Five patients had their first seizure after developing SPMS, which
leads to the assumption that the increased load of cerebral
lesions occurring in MS patients may act as a risk factor for the
development of epilepsy. Four patients suffered from seizures
before RRMS transformed to SPMS. This on the other hand
suggests that epilepsy as a comorbidity of MS could lead to a
higher severity of the disease, to an increasing disability and to
an earlier development of SPMS.
While some authors believe that seizures in MS are usually
harmless and show an adequate response to antiepileptic therapy,
Engelsen et al. in contrary, have the opinion that there is a
poorer prognosis of treatment efficacy of seizures among MS
patients (6). Possibly there is a higher risk for developing status
epilepticus including all its serious consequences in patients with
MS. As described above, in our study, status epilepticus was
confirmed in three individuals, whereas for one patient the data
were inconclusive.
It is possible that MS patients with concomitant seizures
experience a more severe disease course as MS patients without
seizures. Thus, seizures could probably be considered as an
additional factor aggravating disease. This might be because
seizures can affect disability itself and lead to increased neuronal
damage with the resulting consequences (43).
Whether the appearance of both disorders is coincidental
or MS acts as a non-specific trigger for developing seizures
and epilepsy or indeed is the direct cause of seizures is
still under debate (28). However, the increased incidence of
epileptogenic activities in MS patients as compared to the non-
MS population suggests a causal relationship between the two
diseases (26).
CONCLUSION
The findings of this study indicate that there is a higher risk
of developing seizures when having MS as compared to the
general population. The fact that in most cases, seizures occurred
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after the first manifestation of MS indicates that they may
be the consequence of MS. Furthermore, a relation between
certain immunomodulatory therapies and the development
and frequency of seizures in MS patients seems possible
but remains to be proven in further studies due to limited
data availability at present. Moreover, the high frequency of
RRMS and SPMS as well as of focal epilepsy supports the
idea that cortical lesions occurring in MS patients may play
an important role in comorbid epilepsy. Some patients had
their seizures before developing SPMS while seizures in others
appeared after evolving SPMS. This may indicate that epilepsy
is a marker of more aggressive forms of MS but could also
suggest that progressive forms of MS are more likely to
generate seizures.
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